HRP20201469T1 - Derivati tetrahidroizokinolina - Google Patents

Derivati tetrahidroizokinolina Download PDF

Info

Publication number
HRP20201469T1
HRP20201469T1 HRP20201469TT HRP20201469T HRP20201469T1 HR P20201469 T1 HRP20201469 T1 HR P20201469T1 HR P20201469T T HRP20201469T T HR P20201469TT HR P20201469 T HRP20201469 T HR P20201469T HR P20201469 T1 HRP20201469 T1 HR P20201469T1
Authority
HR
Croatia
Prior art keywords
methyl
dihydroisoquinolin
dichlorophenyl
ethanone
chloro
Prior art date
Application number
HRP20201469TT
Other languages
English (en)
Croatian (hr)
Inventor
Anne Valade
Eric JNOFF
Ali Ates
Pierre BURSSENS
David SKOLC
Zara Sands
Benoît MATHIEU
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of HRP20201469T1 publication Critical patent/HRP20201469T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
HRP20201469TT 2014-10-08 2015-10-06 Derivati tetrahidroizokinolina HRP20201469T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives
EP15775688.3A EP3204359B1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
HRP20201469T1 true HRP20201469T1 (hr) 2020-12-11

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201469TT HRP20201469T1 (hr) 2014-10-08 2015-10-06 Derivati tetrahidroizokinolina

Country Status (18)

Country Link
US (1) US10105359B2 (cg-RX-API-DMAC7.html)
EP (1) EP3204359B1 (cg-RX-API-DMAC7.html)
JP (1) JP6622299B2 (cg-RX-API-DMAC7.html)
CN (1) CN107001278B (cg-RX-API-DMAC7.html)
BR (1) BR112017007123B1 (cg-RX-API-DMAC7.html)
CA (1) CA2963951C (cg-RX-API-DMAC7.html)
CY (1) CY1123417T1 (cg-RX-API-DMAC7.html)
DK (1) DK3204359T3 (cg-RX-API-DMAC7.html)
EA (1) EA035544B1 (cg-RX-API-DMAC7.html)
ES (1) ES2821821T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201469T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050664T2 (cg-RX-API-DMAC7.html)
LT (1) LT3204359T (cg-RX-API-DMAC7.html)
PL (1) PL3204359T3 (cg-RX-API-DMAC7.html)
PT (1) PT3204359T (cg-RX-API-DMAC7.html)
RS (1) RS60933B1 (cg-RX-API-DMAC7.html)
SI (1) SI3204359T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016055479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144633A1 (en) * 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
JP6908623B2 (ja) * 2016-04-13 2021-07-28 ユーシービー バイオファルマ エスアールエル テトラヒドロイソキノリン誘導体
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
WO2019105913A1 (en) * 2017-12-01 2019-06-06 Ucb Biopharma Sprl Imaging agents
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MA56440A (fr) 2019-07-01 2022-05-11 UCB Biopharma SRL Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1
CN114008032B (zh) * 2019-07-01 2023-11-10 Ucb生物制药有限责任公司 作为d1正变构调节剂的取代的四氢异喹啉衍生物
WO2021216973A1 (en) * 2020-04-24 2021-10-28 The Regents Of The University Of California Nurr1 receptor modulators and uses thereof
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
JP7591138B2 (ja) * 2020-10-07 2024-11-27 イーライ リリー アンド カンパニー ドーパミンd1受容体ポジティブアロステリック調節因子としてのフェニル-3,4-ジヒドロイソキノリン-2(1h)-イル-エタン-1-オン誘導体
EP4267555A1 (en) * 2020-12-03 2023-11-01 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
CA3202993A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
EP4263522B1 (en) 2020-12-18 2024-10-02 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
IL303688A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Amorphous solid dispersions
JP2024509448A (ja) 2021-03-08 2024-03-01 イーライ リリー アンド カンパニー 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のd1陽性アロステリックモジュレーターの使用
AU2022234226B2 (en) 2021-03-09 2025-08-14 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
CN100509805C (zh) * 2001-12-19 2009-07-08 H.隆德贝克有限公司 3,4-二氢-1h-异喹啉-2-基-衍生物
JP4685861B2 (ja) * 2004-04-29 2011-05-18 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドーパミンアゴニストとしての3−ピペリジニルイソクロマン−5−オール
US20090099158A1 (en) * 2007-03-01 2009-04-16 Grice Cheryl A Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
JP2017530185A (ja) 2017-10-12
SI3204359T1 (sl) 2020-10-30
BR112017007123A2 (pt) 2017-12-19
US10105359B2 (en) 2018-10-23
LT3204359T (lt) 2020-10-12
JP6622299B2 (ja) 2019-12-18
CN107001278A (zh) 2017-08-01
PL3204359T3 (pl) 2021-03-22
CA2963951C (en) 2023-02-28
EP3204359A1 (en) 2017-08-16
RS60933B1 (sr) 2020-11-30
HUE050664T2 (hu) 2020-12-28
PT3204359T (pt) 2020-09-24
ES2821821T3 (es) 2021-04-27
CN107001278B (zh) 2020-11-24
EA035544B1 (ru) 2020-07-03
US20170304292A1 (en) 2017-10-26
EA201790785A1 (ru) 2017-10-31
EP3204359B1 (en) 2020-07-01
CA2963951A1 (en) 2016-04-14
WO2016055479A1 (en) 2016-04-14
BR112017007123B1 (pt) 2023-01-31
DK3204359T3 (da) 2020-09-14
CY1123417T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2017530185A5 (cg-RX-API-DMAC7.html)
TWI883352B (zh) 稠環化合物
RU2018123779A (ru) Новые соединения
JP2016517878A5 (cg-RX-API-DMAC7.html)
JP2016523911A5 (cg-RX-API-DMAC7.html)
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
JP2016500073A5 (cg-RX-API-DMAC7.html)
IL273924B1 (en) Muscarinic acetylcholine M4 receptor antagonists
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
RU2016124178A (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
HRP20200962T1 (hr) Novi spojevi
HRP20171670T1 (hr) Spojevi i sastavi za moduliranje egfr-aktiviteta
RU2018140092A (ru) Новые пиразолпиримидиновые производные
JP2019508384A (ja) 5−置換2−(モルホリン−4−イル)−1,7−ナフチリジン
HRP20150868T1 (hr) Derivati kinolina i kinoksalina kao inhibitori kinaze
HRP20130106T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JP2015523390A (ja) 置換型ピラゾロン化合物及び使用方法
JP2013539777A5 (cg-RX-API-DMAC7.html)
HRP20211678T1 (hr) N-supstituirani derivati indola kao modulatori receptora pge2
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2017532360A5 (cg-RX-API-DMAC7.html)
HRP20170119T1 (hr) Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije
ES2768399T3 (es) Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
JP2020529419A5 (cg-RX-API-DMAC7.html)